Contact
Please use this form to send email to PR contact of this press release:
Clinical Trials at Major University; New Application Targeting Cancer Tumors; IP Portfolio with 9 Patents: NASDAQ: RNXT
TO:
Shaun Bagai, CEO
RenovoRx, Inc.
+1 650-284-4433